Promimic AB (publ)

Hello and welcome to our presentation of the second quarter of 2024. My name is Heidi Bader and I am CFO at Promimic. I am here with our CEO Magnus Larsson. Magnus, can you briefly tell us about the second quarter?

Yes, sure. Promimic is doing an all-time high. We are doing our best quarter so far in the company's history. We have signed a new license agreement and our customers have received four new registered products for clinical treatment. In that regard, we have 18 license agreements and together the customers have 46 products on the market.

That's right. NPI is not growing this quarter. What does that mean?

It is due to the fact that one of our customers has had some problems in their supply chain and their products are delayed. It is now resolved, the product is delivered and we will resume the lost revenue during the third quarter. But in the second half of the year, MPI continues to grow. If we look at license and royalty revenues, it is 17% growth during the quarter and 39% for the second half of the year. Sales of fertilizer and development projects. There we increase with 28% per quarter and 24% per half year. Yes, that's right.

And even more interesting is if we look at this for a total of 12 months, then growth is 48%.

Yes, really. And another thing that can be mentioned this quarter is that we have developed a new process method. We can now also treat heat-sensitive materials and soft polymers. It opens up new business opportunities and we can enter new market segments. Would you like to tell us a little more about the numbers in detail?

Yes, our turnover is up to 12 million kronor and that is 13 percent growth compared to the same quarter last year. Our fixed costs have increased with the move here and our results before the dismissal landed at minus 1 million kronor. With what we have in the pipeline, however, the result will develop positively in the future.

Exciting. And with that we want to end this presentation and thank you for listening.

Thank you.